EUROLAB
iso-226092004-disintegration-time-of-medical-face-mask-materials
Dissolution and Disintegration Testing EMA Guideline on the Investigation of Bioequivalence—Dissolution CriteriaFDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage FormsFDA QbD Dissolution Modeling for PAT IntegrationICH M9 Biopharmaceutics Classification System-based BiowaiversICH Q1A(R2) Stability Testing Impacting Dissolution RateICH Q3C (R8) Residual Solvent Impact on DissolutionICH Q6A Dissolution Testing as Part of SpecificationsICH Q8(R2) Design Space and Dissolution ProfilesICH S6 Dissolution Testing in Biotech-Derived ProductsISO 31101:2019 Dissolution Testing of Oral Hygiene ProductsJP 15th Edition: Dissolution and Disintegration TestJP 3.09 Disintegration Test for Capsules and TabletsJP General Chapter 6.10 Dissolution Test for SuppositoriesPh. Eur. 2.9.1 Disintegration Test for Solid Dosage FormsPh. Eur. 2.9.29 Disintegration of Tablets for Veterinary UsePh. Eur. 2.9.3 Dissolution Testing of Oral Dosage FormsPh. Eur. 2.9.39 Dissolution of Patches and ImplantsPh. Eur. 2.9.4 Dissolution of Modified Release Dosage FormsPh. Eur. 2.9.40 Dissolution Testing for Oral SuspensionsPh. Eur. 2.9.43 In Vitro Dissolution Testing of Inhaled ProductsPh. Int. 2.9.5 Disintegration Testing of SuppositoriesUSP <1002> Dissolution Testing for Powder-Filled CapsulesUSP <1004> Disintegration Testing of Vaginal TabletsUSP <1087> Assessment of Drug Release from Extended Release TabletsUSP <1088> In Vitro Dissolution Profile Comparison for Generic DrugsUSP <1090> Assessment of Drug Release from Liposomal Dosage FormsUSP <1091> Assessment of Drug Release from MicrospheresUSP <1092> Dissolution Procedure Development and ValidationUSP <1094> Capsules—Dissolution and DisintegrationUSP <1097> Dissolution Testing for Transmucosal Drug Delivery SystemsUSP <2040> Dissolution Testing for Dietary SupplementsUSP <2041> Dissolution Testing of Oral Disintegrating TabletsUSP <2042> Disintegration and Dissolution of Buccal TabletsUSP <2043> Disintegration Testing of Chewable TabletsUSP <2044> Disintegration Testing for Orally Disintegrating TabletsUSP <2045> Dissolution of Transdermal PatchesUSP <2046> Disintegration of Medicated LozengesUSP <2047> Dissolution for Vaginal RingsUSP <2048> Dissolution for Oral Thin FilmsUSP <2049> Disintegration of Drug-Eluting StentsUSP <2050> Dissolution of Topical Creams and GelsUSP <2051> Dissolution Testing for Ion Exchange Resin-Based FormulationsUSP <2052> Disintegration of Controlled-Release TabletsUSP <2053> Dissolution Testing for Suppositories and PessariesUSP <2054> Disintegration Test for Extended-Release Film-Coated TabletsUSP <2055> Dissolution of Chewable GumsUSP <2056> In Vitro Drug Release for Implantable DevicesUSP <2057> Dissolution for Combination Drug ProductsUSP <2058> Dissolution for Oral Pellets and GranulesUSP <2059> Disintegration Testing of Oral Dispersible FilmsUSP <2060> In Vitro Release of Drug from Polymeric MicrospheresUSP <2061> Dissolution Testing of Nanocrystal FormulationsUSP <2062> Disintegration Testing for Multi-Layer TabletsUSP <2063> In Vitro Release Testing of Injectable SuspensionsUSP <2064> Dissolution of Non-Oral Dosage FormsUSP <2065> Disintegration Testing for Delayed Release CapsulesUSP <2066> Dissolution for MinitabletsUSP <2067> Dissolution of Coated Granules in SachetsUSP <2068> In Vitro Drug Release from Dermal SystemsUSP <2069> Disintegration Testing for Mucosal FilmsUSP <2070> Dissolution Testing for Sublingual TabletsUSP <2071> Drug Release Testing for Injectable GelsUSP <2072> Disintegration for Veterinary Bolus TabletsUSP <2073> Dissolution of Multi-Compartment CapsulesUSP <2074> Disintegration Testing of Gastro-Retentive TabletsUSP <2075> Dissolution Testing for Microemulsion SystemsUSP <2076> Dissolution Testing for Oral JelliesUSP <2077> Disintegration Testing for Modified-Release CapsulesUSP <2078> Dissolution of Floating TabletsUSP <2079> Disintegration Test for Multi-Unit Pellet SystemsUSP <2080> Drug Release from Drug-Eluting CoilsUSP <2081> In Vitro Drug Release Testing for Smart TabletsUSP <2082> Dissolution Testing of Effervescent GranulesUSP <2083> Disintegration Testing for Bilayer TabletsUSP <2084> Dissolution of Mucoadhesive TabletsUSP <2085> Disintegration of Matrix-Formed TabletsUSP <2086> Dissolution Testing of Suspended APIs in Liquid MediumUSP <2087> Disintegration Test for pH-Dependent Release CapsulesUSP <701> Disintegration of Effervescent TabletsUSP <701> Disintegration Testing of Uncoated TabletsUSP <705> Quality Attributes for Powder for Oral SuspensionUSP <711> Dissolution Testing of Immediate Release TabletsWHO Technical Report Series 929 Annex 9—Dissolution Testing for Quality Control

Comprehensive Guide to ISO 22609:2004 Disintegration Time of Medical Face Mask Materials Laboratory Testing Service

Standard-Related Information

ISO 22609:2004 is an international standard that specifies the requirements for determining the disintegration time of medical face mask materials. The standard is published by the International Organization for Standardization (ISO) and is available in multiple languages, including English, French, German, Italian, Spanish, Portuguese, Russian, Chinese, Japanese, and Korean.

The standard is part of a series of standards that govern the testing and evaluation of medical devices, specifically face masks. The ISO 22609:2004 standard was developed to ensure consistency and comparability in the measurement of disintegration time across different laboratories and countries.

Legal and Regulatory Framework

The use of medical face masks is regulated by various laws and regulations, including:

  • European Union (EU) directives and regulations
  • US Food and Drug Administration (FDA) guidelines
  • International Organization for Standardization (ISO) standards
  • These regulatory bodies require manufacturers to demonstrate compliance with specific requirements, including testing and evaluation of product performance. ISO 22609:2004 is one of the key standards used to assess the disintegration time of medical face mask materials.

    International and National Standards

    Several international and national standards apply to this laboratory test:

  • ISO 14644-1:2015 (Cleanrooms and associated controlled environments - Part 1: Classification of air cleanliness)
  • ASTM F2100-19 (Standard Specification for Performance of Materials Used in Medical Face Masks)
  • EN 14683A2:2007 (Medical face masks - Requirements)
  • TSE ISO 22609:2004 (Turkish Standard equivalent to ISO 22609:2004)
  • These standards provide a framework for testing and evaluating the performance of medical face mask materials, including disintegration time.

    Standard Development Organizations

    The standard development process involves collaboration among various stakeholders, including:

  • International Organization for Standardization (ISO)
  • American Society for Testing and Materials (ASTM)
  • European Committee for Standardization (CEN)
  • Turkish Standards Institution (TSE)
  • These organizations work together to develop and maintain standards that address specific needs and requirements.

    Evolution of Standards

    Standard Numbers and Scope

    The following standard numbers and their scopes apply to this laboratory test:

  • ISO 22609:2004 - Disintegration time of medical face mask materials
  • ASTM F2100-19 - Standard Specification for Performance of Materials Used in Medical Face Masks
  • EN 14683A2:2007 - Medical face masks - Requirements
  • These standards provide a comprehensive framework for testing and evaluating the performance of medical face mask materials.

    Standard Compliance Requirements

    Compliance with ISO 22609:2004 is essential for manufacturers seeking to market their products globally. The standard requires that medical face mask materials meet specific requirements, including disintegration time.

    Consequences of Non-Compliance

    Failure to comply with ISO 22609:2004 can result in:

  • Product rejection or recall
  • Regulatory action and fines
  • Loss of customer confidence and trust
  • Manufacturers must demonstrate compliance with this standard to ensure the safety and effectiveness of their products.

    Industries and Sectors Requiring This Testing

    The following industries and sectors require ISO 22609:2004 testing:

  • Medical device manufacturers
  • Pharmaceutical companies
  • Healthcare providers
  • Regulatory agencies
  • These organizations rely on accurate and reliable testing data to support product development, marketing, and regulatory compliance.

    Risk Factors and Safety Implications

    Non-compliance with ISO 22609:2004 can lead to safety risks, including:

  • Inadequate protection against airborne pathogens
  • Reduced barrier performance
  • Increased risk of infection
  • Manufacturers must ensure that their products meet the requirements specified in this standard to minimize these risks.

    Quality Assurance and Quality Control

    ISO 22609:2004 testing is an essential component of quality assurance and quality control programs. Manufacturers must demonstrate compliance with this standard to ensure product safety and effectiveness.

    Contribution to Product Safety and Reliability

    Compliance with ISO 22609:2004 contributes significantly to product safety and reliability by:

  • Ensuring adequate barrier performance
  • Minimizing the risk of infection
  • Supporting regulatory compliance
  • Manufacturers that prioritize quality assurance and quality control can enhance customer confidence and trust in their products.

    Competitive Advantages

    Performing ISO 22609:2004 testing provides several competitive advantages, including:

  • Demonstrated commitment to product safety and effectiveness
  • Enhanced regulatory compliance
  • Increased customer confidence and trust
  • Improved market positioning
  • Manufacturers that prioritize quality assurance and quality control can differentiate themselves from competitors and maintain a strong market presence.

    Conclusion

    ISO 22609:2004 is an essential standard for medical face mask materials, ensuring consistency and comparability in the measurement of disintegration time across different laboratories and countries. Manufacturers must demonstrate compliance with this standard to ensure product safety and effectiveness, regulatory compliance, and competitive advantage.

    By understanding the importance of ISO 22609:2004, manufacturers can prioritize quality assurance and quality control programs, enhance customer confidence and trust, and maintain a strong market presence.

    Recommendations

    Manufacturers should:

  • Familiarize themselves with the requirements specified in ISO 22609:2004
  • Implement quality assurance and quality control programs that include ISO 22609:2004 testing
  • By following these recommendations, manufacturers can ensure the safety and effectiveness of their products, support regulatory compliance, and maintain a competitive advantage in the market.

    Appendix

    Additional information on ISO 22609:2004 is provided in the following tables:

    Standard Number Title

    --- ---

    ISO 14644-1:2015 Cleanrooms and associated controlled environments - Part 1: Classification of air cleanliness

    ASTM F2100-19 Standard Specification for Performance of Materials Used in Medical Face Masks

    EN 14683A2:2007 Medical face masks - Requirements

    Glossary

    The following terms are used throughout this guide:

  • Disintegration time: The time it takes for a medical face mask material to disintegrate or break down.
  • Barrier performance: The ability of a medical face mask material to prevent the passage of airborne pathogens.
  • Cleanrooms and associated controlled environments: Environments designed to maintain a high level of air cleanliness.
  • These terms are defined in more detail in relevant standards, such as ISO 14644-1:2015.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers